NEW YORK, October 31, 2016 /PRNewswire/ --
Growing concerns that a victory by Democratic nominee Hillary Clinton in the presidential election will result in tighter regulations on pricing for new drugs, continues to disturb the Biotechnology arena, which has already tanked 15.53% this year, as per Investopedia data. Today, Stock-Callers.com reviews
Shares in California headquartered Mast Therapeutics Inc. ended Friday's session flat at $0.08 with a total trading volume of 2.78 million shares. The stock is trading 72.77% below its 50-day moving average. Shares of the Company, which develops therapies for serious or life-threatening diseases with significant unmet needs, have a Relative Strength Index (RSI) of 32.10.
On October 17th, 2016, Mast Therapeutics announced that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into a collaborative agreement with Philips Respironics, Inc., the sleep and respiratory care business of Royal Philips related to the supply of Philips' I-neb® Adaptive Aersol Delivery (AAD™) devices and related consumables for the nebulized delivery of the Company's lead product candidate, AIR001, a sodium nitrite solution for intermittent inhalation. The I-neb® handheld AAD™ system is a small, portable and virtually silent vibrating mesh technology nebulizer system designed to deliver more precise, reproducible doses of medication faster than conventional jet or ultrasonic nebulizers. Free research report on MSTX is available at:
Colorado headquartered Array BioPharma Inc.'s shares saw a decline of 2.02%, closing the day at $5.83 with a total trading volume of 3.66 million shares. The stock has advanced 38.15% in the previous three months and on an YTD basis, each. The Company's shares are trading 18.15% above their 50-day moving average and 59.22% above their 200-day moving average. Additionally, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia/Pacific, have an RSI of 48.40.
On October 25th, 2016, Array BioPharma announced that it will report financial results for Q1 FY17 and hold a conference call to discuss those results on November 1st, 2016 at 9:00 a.m. ET. Ron Squarer, Chief Executive Officer, will lead the call. The Complimentary research report on ARRY can be downloaded at:
Last Friday, shares in California-based Galena Biopharma Inc. dropped 5.64%, closing the session at $0.25. The stock recorded a trading volume of 3.76 million shares, which was higher than its three months average volume of 3.45 million shares. The Company's shares are trading 27.62% below their 50-day moving average. Furthermore, shares of Galena Biopharma, which focuses on developing and commercializing oncology therapeutics that address major unmet medical needs, have an RSI of 32.09.
As per notes files with the SEC on October 26th, 2016, the Special Meeting of stockholders of Galena Biopharma was held on October 21st, 2016. At the Meeting, the company's stockholders voted on the following proposals: i) to approve an amendment to the Company's Amended and Restated Certificate of Incorporation, to effect a reverse stock split of the outstanding shares of the Company's common stock, par value $0.0001 per share, at a ratio of not less than 1 for 2 and not greater than 1 for 20; ii) to authorize the issuance shares of the Company's common stock issuable upon the redemption, conversion or other satisfaction of the Company's obligations under its Amended and Restated 9% Original Issue Discount Senior Secured Debenture due November 10th, 2018 without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Marketplace Rule 5635(d). Visit us today and access our complete research report on GALE at:
Boulder, Colorado headquartered Clovis Oncology Inc.'s shares finished the session 0.94% lower at $30.58 with a total trading volume of 1.69 million shares. The stock has surged 103.32% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 1.94% and 53.19%, respectively. Additionally, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have an RSI of 45.73.
On October 25th, 2016, research firm Chardan Capital Markets initiated a 'Sell' rating on the Company's stock, issuing a target price of $15 per share.
On October 27th, 2016, Clovis Oncology announced that it will publish its Q3 2016 financial results on November 3rd, 2016, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail. Get free access to your research report on CLVS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Appendicitis in children produces symptoms of abdominal pain and swelling, nausea, vomiting and ...
Inflammation is the response of living tissue to injury due to a variety of causes that call upon ...
Bedwetting calculator helps you find solution to the problem and the next step you need to take as ...View All